Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
30 January 2024 - 8:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of January 2024 (Report No.3)
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On January 29, 2024, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Announces Initiation of Patient Recruitment for its Clinical
Trial with SCI-210 in Children with Autism Spectrum Disorder.” A copy of this press release is furnished herewith as Exhibit 99.1
and incorporated by reference herein.
The press release furnished
as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s registration
statements on Form F-3 (File No. 333-275305, File No. 333-269839, File No. 333-266047, File No. 333-233417, File No. 333-248670, File
No. 333-255408, and File No. 333-275305) and on Form S-8 (File No. 333-225773) filed with the Securities and Exchange Commission to be
a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
SciSparc Ltd. |
|
|
|
Date: January 29, 2024 |
By: |
/s/ Oz Adler |
|
Name: |
Oz Adler |
|
Title: |
Chief Executive Officer and Chief Financial Officer |
3
Exhibit 99.1
SciSparc
Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
The
clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process
of SCI-210 first in the Israeli market
TEL AVIV, Israel, Jan. 29, 2024 (GLOBE
NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announces
the initiation of patient recruitment for its clinical trial in children suffering from autism spectrum disorder (“ASD”)
at Soroka Medical Center in Israel.
The
double-blind, randomized and placebo-controlled study will be performed using SciSparc’s proprietary SCI-210, a combination of cannabidiol
(CBD) and CannAmide™(SciSparc’s Palmitoylethanolamide), which is designed to alleviate ASD symptoms. SciSparc will enroll
60 subjects between the ages of five and 18, for 20 weeks, with the purpose of assessing how SCI-210 therapy compares to standard CBD
treatment in managing symptoms of ASD.
The
Company’s goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
“The
initiation of patient recruitment for this clinical study, that has the potential to address an area of unmet medical need, marks an
exciting milestone for the team at SciSparc as it aligns with our mission to improve human health through the development of novel therapies,”
said SciSparc’s Chief Executive Officer, Oz Adler. “We hope the outcome of the trial will enable the Company to procced with
the commercialization process for SCI-210 in Israel.”
The
trial has three primary efficacy metrics: the Aberrant Behavior Checklist-Community (ABC-C) parent questionnaire; the Clinical Global
Impressions-Improvement (CGI-I) performed by a clinician; and the effective therapeutic dose. The trial was designed in consultation
with the National Autism Research Center, the leading research center for autism in Israel.
ASD
is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social
interaction and communication. The term “spectrum” in autism spectrum disorder refers to the wide range of symptoms and severity.
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc
Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s
focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment
of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale
of hemp seeds’ oil-based products on Amazon Marketplace.
Forward-Looking
Statements:
This
press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses
the prospective design and objectives of the clinical trial, the Company’s commercialization intent with regards to SCI-210, the
potential of the clinical study to address ASD, and the potential commercialization of SCI-210 in Israel. Historical results of scientific
research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical
or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations, they are
subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release
are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual
Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission.
Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor
Contact:
IR@scisparc.com
Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2024 to May 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From May 2023 to May 2024